IP Library Granted Patent US 12,343,702
Granted Patent B2
US 12,343,702 · App. 16/978,814 · Granted Jul 1, 2025

Anionic exchange-hydrophobic mixed mode chromatography resin

Inventors: Christopher Belisle (Walnut Creek, CA); Hong Chen (San Ramon, CA); Yueping Xu (Albany, CA); Jiali Liao (San Ramon, CA); Xuemei He (Walnut Creek, CA)
Assignee: BIO-RAD LABORATORIES, INC.
B01J20/289B01D15/3809B01D15/3847B01J20/265B01J20/3085C07K1/165B01J2220/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,343,702
App. No.
16/978,814
Granted
Jul 1, 2025
Kind
B2
Abstract

Chromatography resins having anionic exchange-hydrophobic mixed mode ligands, that are useful for purifying target biomolecules using anionic exchange (i.e., where the ligand is positively charged) and hydrophobic mixed mode chromatography. The chromatography resins allow for efficient purification of target biomolecules (e.g., recombinant proteins, antibodies, antibody-drug conjugates, or antibody derivatives including, but not limited to, antibody fragments and antibody fusions) from a sample, and have been found to be useful in purifying monomeric target biomolecules from aggregate target biomolecules. In an embodiment, the chromatography resins are useful for separating antibodies from one or more components (e.g., contaminants) in the sample.

Claims (86)

1. A chromatography resin having the following formula:

Chromatography matrix-(X)—N(R 1 )(R 2 )—(R 3 -L) n -Ar

or an anionic salt thereof,

wherein:

X is a spacer from the group consisting of —O—CH 2 —, —O—CH 2 —CH 2 —, —O—CH 2 —CH 2 —CH 2 —, —O—CH 2 —CH 2 —CH 2 —CH 2 —, —O—CH 2 —CH(CH 2 —OH)—(O—CH 2 —CH(OH)—CH 2 ) 2 —, —O—CH 2 —CH 2 —CH(CH 2 —OH)—(O—CH 2 —CH 2 —CH(OH)—CH 2 ) 2 —, —O—CH 2 —CH(OH)—CH 2 —, —O—CH 2 —CH 2 —CH(OH)—CH 2 —CH 2 —, —O—CH 2 —CH(OH)—CH 2 —O—CH 2 —CH 2 —CH 2 —CH 2 —O—CH 2 —CH(OH)—CH 2 —, and —CO—NH—C(CH 3 ) 2 —CO—;

R 1 and R 2 are each independently C 1 to C 6 alkyl optionally substituted with —OH;

R 3 is C 2 to C 6 alkyl or C 4 to C 6 cycloalkyl;

L is O;

n is 1 or 2; and

Ar is a phenyl or naphthyl group optionally substituted with up to 5: C 1 to C 3 unsubstituted alkyl, C 3 to C 6 branched alkyl, unsubstituted aryl, or flourine groups; or

a pyridal group optionally substituted with up to four alkyl groups.

2. The chromatography matrix of claim 1 , wherein:

R 1 and R 2 are each independently C 1 to C 3 alkyl;

R 3 is C 2 to C 4 alkyl;

L is O;

n is 1; and

Ar is a phenyl or naphthyl group optionally substituted with up to four C 1 to C 2 unsubstituted alkyl, C 3 to C 4 branched alkyl, or flourine groups; or

a pyridal group optionally substituted with up to three alkyl groups.

3. The chromatography resin of claim 1 , wherein:

X is selected from the group consisting of —O—CH 2 —, —O—CH 2 —CH 2 —, —O—CH 2 —CH 2 —CH 2 —, —O—CH 2 —CH 2 —CH 2 —CH 2 —, and —O—CH 2 —CH(CH 2 —OH)—(O—CH 2 —CH(OH)—CH 2 ) 2 —;

R 1 and R 2 are each independently C 1 or C 2 alkyl;

R 3 is C 2 or C 3 alkyl;

L is O;

n is 1; and

Ar is phenyl, naphthyl, or pyridyl optionally substituted with up to three C 1 to C 2 unsubstituted alkyl.

4. The chromatography resin of claim 1 , wherein Ar is phenyl optionally substituted with one or two C 1 to C 2 unsubstituted alkyl.

5. The chromatography resin of claim 1 , wherein the chromatography resin has one of the following structures, the sphere representing the chromatography matrix and the spacer X:

Resin

Number

13

94

34-1

34-2

86-1

86-2

97-1

97-2

98-1

32-1

91-1

91-2

91-3

91-4

91-5

91-6

32-2

CB216

50-1

71-2

71-4

71-3

71-1

6. The chromatography resin of claim 1 , wherein Ar is unsubstituted.

7. The chromatography resin of claim 1 , wherein Ar is a pyridyl group optionally substituted with up to four alkyl groups.

8. The chromatography resin of claim 1 , wherein the anionic salt is a hydrochloride salt or a sulfate salt.

9. The chromatography resin of claim 1 , wherein X is attached to chromatography matrix via an amine, ether or amide bond.

10. A chromatography resin having the following formula:

Chromatography matrix-(X)—N(R 1 )—[(R 3 -L) n -Ar] 2

or an anionic salt thereof,

wherein:

X is a spacer from the group consisting of —O—CH 2 —, —O—CH 2 —CH 2 —, —O—CH 2 —CH 2 —CH 2 —, —O—CH 2 —CH 2 —CH 2 —CH 2 —, —O—CH 2 —CH(CH 2 —OH)—(O—CH 2 —CH(OH)—CH 2 ) 2 —, —O—CH 2 —CH 2 —CH(CH 2 —OH)—(O—CH 2 —CH 2 —CH(OH)—CH 2 ) 2 —, —O—CH 2 —CH(OH)—CH 2 —, —O—CH 2 —CH 2 —CH(OH)—CH 2 —CH 2 —, —O—CH 2 —CH(OH)—CH 2 —O—CH 2 —CH 2 —CH 2 —CH 2 —O—CH 2 —CH(OH)—CH 2 —, and —CO—NH—C(CH 3 ) 2 —CO—;

R 1 is C 1 to C 6 alkyl optionally substituted with —OH;

R 3 is C 2 to C 6 alkyl or C 4 to C 6 cycloalkyl;

L is O;

n is 1; and

Ar is a phenyl or naphthyl group optionally substituted with up to 5: C 1 to C 3 unsubstituted alkyl, C 3 to C 6 branched alkyl, unsubstituted aryl, or flourine groups; or

a pyridal group optionally substituted with up to four alkyl groups.

11. The chromatography resin of claim 10 , wherein:

X is selected from the group consisting of —O—CH 2 —, —O—CH 2 —CH 2 —, —O—CH 2 —CH 2 —CH 2 —, —O—CH 2 —CH 2 —CH 2 —CH 2 —, —O—CH 2 —CH(CH 2 —OH)—(O—CH 2 —CH(OH)—CH 2 ) 2 —, —O—CH 2 —CH 2 —CH(CH 2 —OH)—(O—CH 2 —CH 2 —CH(OH)—CH 2 ) 2 —, —O—CH 2 —CH(OH)—CH 2 —, —O—CH 2 —CH 2 —CH(OH)—CH 2 —CH 2 —, —CH 2 —CH(OH)—CH 2 —O—CH 2 —CH 2 —CH 2 —CH 2 —O—CH 2 —CH(OH)—CH 2 —, and —CO—NH—C(CH 3 ) 2 —CO—;

R 1 is C 1 to C 3 alkyl;

R 3 is C 2 to C 4 alkyl;

L is O;

n is 1; and

L is O;

n is 1; and

Ar is a phenyl or naphthyl group optionally substituted with up to four C 1 to C 2 unsubstituted alkyl, C 3 to C 4 branched alkyl, or flourine groups; or

a pyridal group optionally substituted with up to three alkyl groups.

12. The chromatography resin of claim 11 , wherein:

X is selected from the group consisting of —O—CH 2 —, —O—CH 2 —CH 2 —, —O—CH 2 —CH 2 —CH 2 —, —O—CH 2 —CH 2 —CH 2 —CH 2 —, and —O—CH 2 —CH(CH 2 —OH)—(O—CH 2 —CH(OH)—CH 2 ) 2 —;

R 1 is C 1 or C 2 alkyl;

R 3 is C 2 or C 3 alkyl; and

L is O;

n is 1; and

Ar is phenyl, naphthyl, or pyridyl optionally substituted with up to three C 1 to C 2 unsubstituted alkyl.

13. The chromatography resin of claim 10 , wherein Ar is phenyl optionally substituted with one or two C 1 to C 2 unsubstituted alkyl.

14. The chromatography resin of claim 10 , wherein the chromatography resin has one of the following structures, the sphere representing the chromatography matrix and the spacer X:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2020
From: BELISLE, CHRISTOPHER; CHEN, HONG; XU, YUEPING; LIAO, JIALI; HE, XUEMEI
To: BIO-RAD LABORATORIES, INC.
Reel/Frame 054622/0266 →
Continuity (3)
Provisional Application 62647202 · Mar 23, 2018
Provisional Application 62640430 · Mar 8, 2018
Related Publication 20200406232A1 · Dec 31, 2020
References Cited (89)
US 5429746A · Shadle et al. · 1995 [cited by applicant]
US 5645717A · Hjerten et al. · 1997 [cited by applicant]
US 5647979A · Liao et al. · 1997 [cited by applicant]
US 5652348A · Burton et al. · 1997 [cited by applicant]
US 5935429A · Liao et al. · 1999 [cited by applicant]
US 5945520A · Burton et al. · 1999 [cited by applicant]
US 6423666B1 · Liao et al. · 2002 [cited by applicant]
US 6498236B1 · Lihme et al. · 2002 [cited by applicant]
US 7714112B2 · Engstrand et al. · 2010 [cited by applicant]
US 7867784B2 · Engstrand et al. · 2011 [cited by applicant]
US 8748582B2 · Hearn et al. · 2014 [cited by applicant]
US 8895710B2 · Engstrand et al. · 2014 [cited by applicant]
US 9169331B2 · Liu et al. · 2015 [cited by applicant]
US 9309282B2 · Liao et al. · 2016 [cited by applicant]
US 9486799B2 · Pohl · 2016 [cited by applicant]
US 9669402B2 · Liao et al. · 2017 [cited by applicant]
US 9975920B2 · Aldinger et al. · 2018 [cited by applicant]
US 10287314B2 · Bian et al. · 2019 [cited by applicant]
US 10457749B2 · Fouque et al. · 2019 [cited by applicant]
US 10487138B2 · Felföldi et al. · 2019 [cited by applicant]
US 10682640B2 · Liao et al. · 2020 [cited by applicant]
US 10947268B2 · Li et al. · 2021 [cited by applicant]
US 11305271B2 · Yavorsky et al. · 2022 [cited by applicant]
US 11896969B2 · Belisle et al. · 2024 [cited by applicant]
US 20060052598A1 · Burton et al. · 2006 [cited by applicant]
US 20070112178A1 · Johansson et al. · 2007 [cited by applicant]
US 20070244307A1 · Engstrand et al. · 2007 [cited by applicant]
US 20090270596A1 · Gagnon et al. · 2009 [cited by applicant]
US 20110139717A1 · Malenfant et al. · 2011 [cited by applicant]
US 20110266225A1 · Johansson et al. · 2011 [cited by applicant]
US 20120116027A1 · Rasmussen et al. · 2012 [cited by applicant]
US 20120259094A1 · Hearn et al. · 2012 [cited by applicant]
US 20130131318A1 · Kremer et al. · 2013 [cited by applicant]
US 20130237692A1 · Liao et al. · 2013 [cited by applicant]
US 20130289247A1 · Kremer et al. · 2013 [cited by applicant]
US 20150073128A1 · Engstrand et al. · 2015 [cited by applicant]
US 20150299248A1 · Maloisel et al. · 2015 [cited by applicant]
US 20160272673A1 · Althouse et al. · 2016 [cited by applicant]
US 20170232433A1 · Liao et al. · 2017 [cited by applicant]
US 20170334948A1 · Bittermann et al. · 2017 [cited by applicant]
US 20180127460A1 · Hall et al. · 2018 [cited by applicant]
US 20180154281A1 · Engstrand et al. · 2018 [cited by applicant]
US 20180215786A1 · Kozlov et al. · 2018 [cited by applicant]
US 20190119415A1 · Graalfs · 2019 [cited by applicant]
US 20210069692A1 · Belisle et al. · 2021 [cited by applicant]
AU 200173432 · 2002 [cited by applicant]
CN 101060931 · 2007 [cited by applicant]
CN 102762585 · 2012 [cited by applicant]
CN 103189390 · 2013 [cited by applicant]
CN 103877748 · 2014 [cited by applicant]
CN 103998456 · 2014 [cited by applicant]
CN 109790201 · 2019 [cited by applicant]
WO 1990012632A1 · 1990 [cited by applicant]
WO 1997029825A1 · 1997 [cited by applicant]
WO 2006043896A1 · 2006 [cited by applicant]
WO WO2010117598A2 · 2010 [cited by examiner]
WO WO2011044637 · 2011 [cited by applicant]
WO WO2011104307 · 2011 [cited by applicant]
WO WO2013134251 · 2013 [cited by applicant]
WO WO2019152977 · 2019 [cited by applicant]
PubChem ID 26050, “N,N-Dimethyl-2-phenoxyethanamine” Mar. 26, 2005, pp. 1-14. [cited by applicant]
Written Opinion in International Application No. PCT/US2019/021376, Jul. 9, 2019, pp. 1-7. [cited by applicant]
Extended European Search Report for EP 19764738.1, Jul. 30, 2021, pp. 1-13. [cited by applicant]
Li, Y. et al. “New reversed-phase/anion-exchange/hydrophilic interaction mixed-mode stationary phase based on dendritic polymer-modified porous silica” [cited by applicant]
De Koning et al., “Crosslinked agarose encapsulated sorbents resistant to steam sterilization. Preparation and mechanical properties” Journal of Biomedical Materials Research, vol. 18, 1984, pp. 1-13. [cited by applicant]
Horejsi, et al.; “The Isolation of Gamma Globulin from Blood-Serum by Rivanol”; Acta Medica Scandinavica; vol. CLV, fasc. I; submitted for publication Mar. 27, 1956; pp. 65-70. [cited by applicant]
Emöd, et al.; “Five Sepharose-Bound Ligands for the Chromatographic Purification of Clostridium Collagenase and Clostripain”; FEBS Letters; vol. 77, No. 1; May 1977; pp. 51-56. [cited by applicant]
Miller; “Rivanol, Resin and the Isolation of Thrombins”; Nature; vol. 184; Aug. 8, 1959; p. 450. [cited by applicant]
Abraham; “Solid-Phase Radioimmunoassay of Estradiol-17β”; Preliminary Communications, The Endocrine Society; vol. 29; Jun. 1969; pp. 865-870. [cited by applicant]
Te Booy, et al.; “Large-scale purification of factor Vill by affinity chromatography: optimization of process parameters”; J. of Chromatography; vol. 503; 1990; pp. 103-114. [cited by applicant]
Te Booy, et al.; “Affinity purification of plasma proteins: characterization of six affinity matrices and their application for the isolation of human factor VIII”; Thromb. Haemost.; vol. 61(2); Apr. 1989; pp. 234-237. [cited by applicant]
Sato, et al.; “Development of Mammalian Serum Albumin Affinity Purification Media by Peptide Phage Display”; Biotechnol. Prog. vol. 18; Jan. 26, 2002; pp. 182-192. [cited by applicant]
Anspach; “Endotoxin removal by affinity sorbents”; J. Biochem. Biophys. Methods; vol. 49; 2001; pp. 665-681. [cited by applicant]
Nemoto, et al.; “Newly Developed Immobilized Polymyxin B Fibers Improve the Survival of Patients with Sepsis”; Blood Purif.; vol. 19; 2001; pp. 361-369. [cited by applicant]
Jaber, et al.; “Extracorporeal Adsorbent-Based Strategies in Sepsis”; American J of Kidney Diseases; vol. 30, No. 5, Suppl 4; Nov. 1997; pp. S44-S56. [cited by applicant]
Persson, et al.; “Purification of Antibody and Antibody-Fragment From E. coli Homogenate Using 6,9-Diamino-2-ethoxyacridine Lactate as Precipitation Agent”; Biotechnology and Bioengineering; vol. 87, No. 3, Aug. 5, 2004… [cited by applicant]
Franek; “Purification of IgG Monocloanl Antibodies from Ascitic Fluid Based on Rivanol Precipitation”; Methods in Enzymology; vol. 121; 1986; 631-638. [cited by applicant]
Simmons, et al.; “Expression of full-length immunoglobulins in [cited by applicant]
Petsch, et al.; “Endotoxin removal from protein solutions”; J. of Biotechnology; vol. 76; 2000; pp. 97-119. [cited by applicant]
Mayer, et al.; “Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)”; British J. of Cancer; vol. 90; May 25, 2004; pp. 2402-2… [cited by applicant]
Talmadge, et al.; “Efficient Endotoxin Removal with a New Sanitizable Affinity Column; Affi-Prep Polymyxin”; J. of Chromatography; vol. 476; 1989; pp. 175-185. [cited by applicant]
Elder, et al.; “Evaluation of Quaternary Aminoethy-Sephadex A50 Column Chromatography for Detection of Anti-Cytomegalovirus Immunoglobulin M”; Mayo Clin Proc; vol. 62; May 1987; pp. 345-350. [cited by applicant]
Fung, et al.; “Serologic Diagnosis of Toxoplasmosis with Emphasis on the Detection of Toxoplasma-specific Immunoglobulin M Antibodies”; American Journal of Clinical Pathology; vol. 83, No. 2; Feb. 1983; pp. 196-199. [cited by applicant]
Joustra, et al.; “Preparation of Freeze-dried, Monomeric and Immunochemically Pure IgG by a Rapid and Reproducible Chromatographic Technique”; from Protides of the Biological Fluids, Chapter D: Techniques; Published by … [cited by applicant]
Jelezarova, et al.; “Interaction of C3b2-IgG complexes with complement proteins properdin, factor B and factor H: Implications for amplification”; Biochem J.; vol. 349; 2000; pp. 217-223. [cited by applicant]
Eriksson. K. et al. “MAb Contaminant Removal with a Multimodal Anion Exchanger A Platform Step to Follow Protein A” [cited by applicant]
European Search Report for EP 19764738.1, May 7, 2021, pp. 1-13. [cited by applicant]
PubChem CID 37732, Mar. 26, 2005, pp. 1-17. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2020/49305, Feb. 5, 2021, pp. 1-11. [cited by applicant]